3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Kaitlyn Allen of MendIt, Miguel Calatayud of iwi, and Tatiana Fofanova of Koda Health. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sustainability to health tech — recently making headlines in Houston innovation.

Kaitlyn Allen, founder and chief strategy officer of MendIt

MendIt seeks to reduce textile waste by providing an easy-to-use app to make menders and customizers more accessible. Photo courtesy of MendIt

Kaitlyn Allen thought she had a great idea for a company — something that can help people repair clothing conveniently. And all of the pieces of the strategy already existed. There are plenty of seamstressing businesses around town, but not an easy way to navigate them. “

There’s a disconnect. There’s a market of people who potentially want to mend their clothes, but there’s no easy way of finding or accessing that service,” she says. “With this next generation, you need to meet them where they are.”

And where they are, Allen says, is on their phones.

MendIt is completing a pilot program with one mender — Connect Community in Gulfton area — in partnership with St. Luke's Gethsemane on Bellaire in Sharpstown. She also hopes to tap into a local artist who can help with customization — like embroidery, for instance. Click here to read more.

Miguel Calatayud, CEO of iwi

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

Miguel Calatayud feels like he has the perfect storm of a product. Not only does his company iwi's nutritional supplement have a sustainability focus, it's also just a very competitive product in the marketplace. The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2.

"We've been growing significantly for one main reason," Calatayud says. "It works."

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the Houston Innovators podcast. Click here to read more.

Tatiana Fofanova, co-founder and CEO of Koda Health

Tatiana Fofanova, co-founder and CEO of Koda, closed recent funding for the digital health startup. Image via LinkedIn

Tatiana Fofanova, Koda co-founder and CEO, has something to celebrate. The Houston-based startup announced this month that it raised $3.5 million in its latest seed round. The funding will be used to help the digital advanced care planning company double the size of its team in the next six months.

"Koda Health helps vulnerable people navigate and communicate difficult decisions about their health care journey. So, when hiring, we look for empathetic people who are phenomenal communicators," Tatiana Fofanova, Koda co-founder and CEO, says in a statement.

The Koda team will also use the funds to expand its operations to all 50 states. According to the statement, the team plans to focus on low-resource communities and operating in different languages. Click here to read more.

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

How this Houston innovator plans to make a sustainable impact — one algae farm at a time

Houston innovators podcast episode 120

If there's one thing Miguel Calatayud is passionate about it's conscious capitalism — and specifically that his company, iwi, a Houston-based food and nutritional supplement company, is striking the perfect balance between impact and profit.

The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2. Calatayud says the farms even area able to reuse 98 percent of the water involved in the process.

"In the past, you had to choose between making an impact and making a profit," Calatayud says on this week's episode of the Houston Innovators Podcast. "In our case, the way we built the company and the business model we put together, it's actually the opposite. The bigger the impact we make, the bigger the business we're creating."

With all this sustainability to boast about, Calatayud says it's not even the best part. Iwi's products, which include Omega-3 supplements, multivitamins, and even a forthcoming protein — all made from the farmed algae, are also very competitive products in the market.

"We've been growing significantly for one main reason," Calatayud says." It works."

"That's what's really driving the growth in the company because once a customer starts taking iwi, they don't go back to whatever they were taking before," Calatayud continues on the show.

Calatayud says iwi is ready to expand more internationally. The company recently closed an $8 million deal — $5.5 million in senior secured term debt and a $2.5 million direct equity investment — with GP Capital Partners, an investor and strategic partner for the company. The influx of funding will help iwi accelerate sales of its existing products and ramp up development, marketing, and growth of new protein-based product, according to the release. Iwi will also enter new international markets.

"What we are going to do with [GP] and other investors that we have is to take this brand to the next level," Calatayud says. "Last year, we grew 91 percent. This year, we are planning to grow around 200 percent."

Calatayud says the pond systems iwi operates are replicable, and as the company grows he could see building these types of algae farms across the world and even in the Middle East, creating jobs and opportunities globally.

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings